www.vectorbiopharma.com Open in urlscan Pro
35.230.133.18  Public Scan

Form analysis
1 forms found in the DOM

POST https://www.vectorbiopharma.com/wp-comments-post.php?wpe-comment-post=vectorbiophar1

<form action="https://www.vectorbiopharma.com/wp-comments-post.php?wpe-comment-post=vectorbiophar1" method="post" id="commentform" class="comment-form" novalidate="">
  <p class="comment-notes"><span id="email-notes">Your email address will not be published.</span> <span class="required-field-message" aria-hidden="true">Required fields are marked <span class="required" aria-hidden="true">*</span></span></p>
  <p class="comment-form-comment"><label for="comment">Comment <span class="required" aria-hidden="true">*</span></label> <textarea id="comment" name="comment" cols="45" rows="8" maxlength="65525" required=""></textarea></p>
  <p class="comment-form-author"><label for="author">Name <span class="required" aria-hidden="true">*</span></label> <input id="author" name="author" type="text" value="" size="30" maxlength="245" required=""></p>
  <p class="comment-form-email"><label for="email">Email <span class="required" aria-hidden="true">*</span></label> <input id="email" name="email" type="email" value="" size="30" maxlength="100" aria-describedby="email-notes" required=""></p>
  <p class="comment-form-url"><label for="url">Website</label> <input id="url" name="url" type="url" value="" size="30" maxlength="200"></p>
  <p class="comment-form-cookies-consent"><input id="wp-comment-cookies-consent" name="wp-comment-cookies-consent" type="checkbox" value="yes"> <label for="wp-comment-cookies-consent">Save my name, email, and website in this browser for the next time
      I comment.</label></p>
  <p class="form-submit"><input name="submit" type="submit" id="submit" class="submit" value="Post Comment"> <input type="hidden" name="comment_post_ID" value="868" id="comment_post_ID">
    <input type="hidden" name="comment_parent" id="comment_parent" value="0">
  </p>
</form>

Text Content

Skip to content
 * Home
 * About
 * People
 * Technology
 * Publications
 * Partnering
 * Investors
 * Careers
 * News
 * Contact


PIONEERS IN DELIVERING MEDICINES OF THE FUTURE


ABOUT US

Vector BioPharma is a biopharmaceutical company aiming to transform the safety,
efficacy, and specificity of drug delivery, to improve treatments for patients.
Incorporating cutting-edge platform technologies, from world-class academic
research at the University of Zürich, Vector BioPharma uses engineered
adenoviral vectors to achieve cell- and tissue-specific delivery, and tunable
expression of genes and regulators with unprecedented precision.


OUR MISSION

We develop next-generation therapeutics using our proprietary platform that
delivers the right gene to the right place at the right time with unparalleled
precision and versatility.


THE VECTOR BIOPHARMA TEAM




PEOPLE

Management team
Founders
Board of directors


LORENZ MAYR

Lorenz Mayr, Ph.D. is the Chief Executive Officer and co-founder of Vector
BioPharma. A biochemist, biophysicist and molecular biologist by training, he
started his industry career at Bayer, subsequently assuming global roles of
increasing responsibility at Novartis (Executive Director), AstraZeneca (VP and
Global Head, Reagents and Assay Development), and GE Healthcare Life Sciences
(Chief Technology Officer, Head of R&D). Prior to joining Vector, Lorenz was
Entrepreneur-in-Residence at Syncona. He holds Board positions at Phoremost,
Mogrify and at Fraunhofer IGB, IPA and IZI. He is Chief Scientific Advisor to
EQT Investments AB and holds a position as Guest Professor, Institute of
Molecular Health Sciences at the ETH in Zürich. He trained at the University of
Tübingen (Germany), University of Bayreuth (Germany), University of Colorado at
Boulder (USA) and at Massachusetts Institute of Technology (Cambridge, Mass,
USA).

Read more


SHEENA SMITH

Sheena Smith, Ph.D., is the Head of Program Management at Vector BioPharma. She
is a protein engineer with expert knowledge of gene and cell therapy,
biochemical immunology, and directed evolution. Prior to joining Vector
BioPharma AG as one of the first employees in 2021, Sheena did her post doc at
the University of Zürich where she lead the first in vivo studies for SHREAD
delivery of cancer therapeutics, which provided the foundation for Vector
BioPharma and its proprietary Precision Gene Delivery Technology. Sheena has
over 15 years of experience in biomedical research and has been an inventor of
platform technologies in T cell receptor engineering and adenoviral gene
therapy. In this field she has authored numerous peer-reviewed publications and
holds several patents. She holds her Ph.D. in Biochemistry from the University
of Illinois at Urbana-Champaign in the USA.

Read more


NICHOLAS (NIK) BARBET

Nicholas (Nik) Barbet, D. Phil, is Head of Operations at Vector BioPharma. A
biochemist and molecular biologist by training, he joined Vector Biopharma from
Corlieve Therapeutics AG (Paris, France), a biotechnology company developing
gene therapies for the treatment of epilepsy.  Nik began his industry career in
clinical research at Ciba Geigy AG/ Novartis AG  (Basel, Switzerland). He moved
to F. Hoffmann La Roche in 2000, where he gained extensive experience in
clinical development, project management and project leadership in oncology,
cardiometabolic diseases and neuroscience, alliance management, finance,
procurement and business operations.  He trained at University of Bath (UK),
university of Sussex (UK), University of Basel (Switzerland), IMD (Lausanne,
Switzerland) and London Business School (London, UK).

Read more


KERRY THORNTON

Kerry Thornton, BA Hons, is the Executive Assistant at Vector BioPharma and a
member of the Management team. She has extensive experience in administrative
and managerial roles in the Pharma  and airline industries, joining Vector from
F. Hoffmann La Roche (Basel, Switzerland), where she was an Administrative
Professional and Business Manager to the Global Head of Program Management in
Product Development. She holds a Bachelor of Arts in Modern Languages from the
University of Liverpool.

Read more


LORENZ MAYR, PH.D

Lorenz Mayr, Ph.D. is the Chief Executive Officer and co-founder of Vector
BioPharma. A biochemist, biophysicist and molecular biologist by training, he
started his industry career at Bayer, subsequently assuming global roles of
increasing responsibility at Novartis (Executive Director), AstraZeneca (VP and
Global Head, Reagents and Assay Development), and GE Healthcare Life Sciences
(Chief Technology Officer, Head of R&D). Prior to joining Vector, Lorenz was
Entrepreneur-in-Residence at Syncona. He holds Board positions at Phoremost,
Mogrify and at Fraunhofer IGB, IPA and IZI. He is Chief Scientific Advisor to
EQT Investments AB and holds a position as Guest Professor, Institute of
Molecular Health Sciences at the ETH in Zürich. He trained at the University of
Tübingen (Germany), University of Bayreuth (Germany), University of Colorado at
Boulder (USA) and at Massachusetts Institute of Technology (Cambridge, Mass,
USA).

Read more


ANDREAS PLÜCKTHUN

Andreas Plückthun, PhD, is scientific co-founder of Vector BioPharma and a
member of the Board of Directors. He is a full professor of biochemistry at the
University of Zürich. An internationally recognized pioneer in protein
engineering, his research has made fundamental scientific contributions to the
field, resulting in development of synthetic antibodies, ribosome display, the
Designed Ankyrin Repeat Protein (DARPin) technology and stable GPCRs for
structure-based drug development. He is an elected member of the German National
Academy of Science Leopoldina and the European Molecular Biology Organization
and is recipient of numerous international awards for his research.

Prof. Plückthun is co-founder of Morphosys AG (Munich, Germany), Molecular
Partners AG (Zürich, Switzerland) and G7 Therapeutics (now Heptares, part of the
Sosei Group). He trained in chemistry at the University of Heidelberg, received
his PhD from the University of California at San Diego, and was postdoc at
Harvard University, and then group leader at the Max-Planck Institute for
Biochemistry (Martinsried, Germany).

Read more


ALEXANDER MAYWEG

Alexander Mayweg, Ph.D., is Chairman of the Board of Vector BioPharma and also
serves as head of Ridgeline Therapeutics, Versant’s Basel-based Discovery
Engine. Alex is an accomplished leader in drug discovery and medicinal chemistry
across Europe, the U.S. and Asia. He brings to Versant deep operating
capabilities, having led successful therapeutics portfolios, programs and teams
within Roche Pharma Research and Early Development.

Since joining Versant in 2016, he has been involved in launching and investing
in a number of Versant’s portfolio companies including Black Diamond (BDTX),
Monte Rosa (GLUE), Bright Peak, Enterprise (acquired), T-knife and Matterhorn.

Read more


MARKUS ENZELBERGER

Markus Enzelberger is a partner located in Basel where he plays a central role
in the launch of future newcos from Versant’s Ridgeline Discovery Engine.

He is a seasoned executive with deep domain knowledge of drug discovery and
development, especially in the protein field. Markus most recently was CSO and a
member of the management board of MorphoSys. He joined the company in 2002 and
is recognized as an authority in the field of protein engineering.

Read more


ANDREAS PLÜCKTHUN

Andreas Plückthun, PhD, is scientific co-founder of Vector BioPharma and a
member of the Board of Directors. He is a full professor of biochemistry at the
University of Zürich. An internationally recognized pioneer in protein
engineering, his research has made fundamental scientific contributions to the
field, resulting in development of synthetic antibodies, ribosome display, the
Designed Ankyrin Repeat Protein (DARPin) technology and stable GPCRs for
structure-based drug development. He is an elected member of the German National
Academy of Science Leopoldina and the European Molecular Biology Organization
and is recipient of numerous international awards for his research.

Prof. Plückthun is co-founder of Morphosys AG (Munich, Germany), Molecular
Partners AG (Zürich, Switzerland) and G7 Therapeutics (now Heptares, part of the
Sosei Group). He trained in chemistry at the University of Heidelberg, received
his PhD from the University of California at San Diego, and was postdoc at
Harvard University, and then group leader at the Max-Planck Institute for
Biochemistry (Martinsried, Germany).

Read more


TECHNOLOGY

Vector BioPharma’s cutting-edge gene precision delivery technology will
transform the safety, efficacy, and specificity of biologics and cell therapies.

Our Shielded, Retargeted Adenovirus (SHREAD) platform, harnesses the
non-replicative, high-capacity properties of adenoviral vectors (HCAdVs)
combined with exogenous, high-avidity adapter proteins to redirect delivery of
DNA encoding therapeutics to defined biomarkers on the target cell or tissue, in
a highly controlled manner.

This allows for the local production of highly potent drugs with greatly reduced
risk of systemic toxicities.


SELECTED PUBLICATIONS

Freitag et al. Modular Adapters Utilizing Binders of Different Molecular Types
Expand Cell-Targeting Options for Adenovirus Gene Delivery Bioconj Chem (2022)

Kirchhammer et al. NK cells with tissue-resident traits shape response to
immunotherapy by inducing adaptive antitumor immunity. Sci Transl Med (2022)

Smith SN et al. The SHREAD gene therapy platform for paracrine delivery improves
tumor localization and intratumoral effects of a clinical antibody. Proc
National Acad Sci USA (2021)

Brücher D et al. iMATCH: an integrated modular assembly system for therapeutic
combination high-capacity adenovirus gene therapy. Mol Ther Methods Clin Dev
(2021)

Schmid M et al. Adenoviral vector with shield and adapter increases tumor
specificity and escapes liver and immune control. Nat Comm (2018)

Dreier B et al. Development of a generic adenovirus delivery system based on
structure-guided design of bispecific trimeric DARPin adapters. Proc National
Acad Sci USA (2013)




PARTNERING

Vector BioPharma is a pharmaceutical company developing its own therapeutic
products. The Company’s proprietary delivery technology is available to license
by innovative companies with new modalities.

We are looking to partner with pioneers in the fields of cell therapies,
precision medicine, and academic researchers to revolutionize gene delivery.


CURRENT PARTNERS

University of Zürich

Ridgeline Discovery



INVESTORS

Vector BioPharma will commercialize its technology via the development of
therapeutics and is initially focused on immuno-oncology. The Company’s
adenoviral vectors can be used to deliver genes and gene regulators to
facilitate the use of next-generation treatment modalities working with DNA,
including in-situ expression of immune checkpoint inhibitors and CAR T cell
therapies.

Following a successful Series A round in 2021, Vector Biopharma will continue to
invest in technology development. We welcome inquiries from investors ahead of
our Series B investment round.


CURRENT INVESTORS

Versant Ventures



CAREERS

Vector BioPharma values diversity and inclusion and is committed to supporting
its team’s personal and career development. If you’d like to find out more about
career opportunities at Vector BioPharma, access our current vacancies through
our partner’s hiring portal.

CURRENT VACANCIES


LOCATION

Founded in 2021, Vector BioPharma is headquartered in Basel, Switzerland.
Situated at the very heart of Europe, bordering France and Germany, Basel boasts
diversity, great quality of life and one of the largest pools of pharma talent.


NEWS

Jan 10, 2023
Vector BioPharma and iBET collaborate to develop high-throughput analytical
methods and scalable processes for gene delivery
Aug 11, 2022
Versant Ventures Launches Vector BioPharma AG


LEAVE A REPLY CANCEL REPLY

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.



© Copyright Vector BioPharma 2023
Terms of Use Cookie policy
Web Design by Douglass Digital